Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 13:13:915362.
doi: 10.3389/fneur.2022.915362. eCollection 2022.

Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study

Enrico Premi  1 , Valentina Cantoni  2   3 , Alberto Benussi  2   4 , Nicola Gilberti  1 , Veronica Vergani  1 , Ilenia Delrio  1 , Massimo Gamba  1 , Raffaella Spezi  1 , Angelo Costa  1 , Alessandro Padovani  2   4 , Barbara Borroni  2   4 , Mauro Magoni  1
Affiliations

Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study

Enrico Premi et al. Front Neurol. .

Abstract

Background: Recent research on animal models of ischemic stroke supports the idea that pharmacological treatment potentially enhancing intrinsic brain plasticity could modulate acute brain damage, with improved functional recovery. One of these new drugs is citicoline, which could provide neurovascular protection and repair effects.

Objectives: The objective of this randomized, single-blind experimental study was to evaluate whether the treatment with Rischiaril® Forte was able to restore intracortical excitability measures, evaluated through transcranial magnetic stimulation (TMS) protocols, in patients with acute ischemic stroke.

Methods: Patients with acute ischemic stroke were recruited and assigned to an eight-week therapy of standard treatment (control group - CG) or CDP-choline (Rischiaril® Forte, containing 1,000 mg of citicoline sodium salt) added to conventional treatment (treatment group - TG). Each subject underwent a clinical evaluation and neurophysiological assessment using TMS, pretretament and posttreatment.

Results: A total of thirty participants (mean [SD] age, 68.1 [9.6] years; 11 women [37%]) completed the study. We did not observe significant changes in clinical scores after CDP-choline treatment (all p > 0.05), but we observed a significant improvement in short-interval intracortical inhibition (SAI) (p = 0.003) in the TG group compared to the CG group.

Conclusions: The eight-week treatment with citicoline after acute ischemic stroke may restore intracortical excitability measures, which partially depends on cholinergic transmission. This study extends current knowledge of the application of citicoline in acute ischemic stroke.

Keywords: cholinergic system (CS); citicoline; short-latency afferent inhibition (SAI); stroke; transcranial magnetic stimulation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
SAI measures before and after exposure to CDP-choline treatment. SAI, short-latency afferent inhibition. Error bars represent standard errors. *Significant difference.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. . Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. (2021) 20:1–26. 10.1016/S1474-4422(21)00252-0 - DOI - PMC - PubMed
    1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. . Executive summary: heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation. (2012) 125:188–97. 10.1161/CIR.0b013e3182456d46 - DOI - PubMed
    1. Zhang X, Bi X. Post-stroke cognitive impairment: a review focusing on molecular biomarkers. J Mol Neurosci. (2020) 70:1244–54. 10.1007/s12031-020-01533-8 - DOI - PubMed
    1. Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, et al. . Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. (2012) 380:349–57. 10.1016/S0140-6736(12)60813-7 - DOI - PubMed
    1. Overgaard K. The effects of citicoline on acute ischemic stroke: a review. J Stroke Cerebrovasc Dis. (2014) 23:1764–9. 10.1016/j.jstrokecerebrovasdis.2014.01.020 - DOI - PubMed